Molecular Detection

About

Q&A

What is Molecular Detection's primary focus?

Molecular Detection is developing SEPSIS-xxpress, a hospital-based instrument designed for rapid sepsis diagnosis and pathogen profiling.

What problem does Molecular Detection's product aim to solve?

The SEPSIS-xxpress system aims to provide doctors with specific pathogen and antibiotic-resistance profiles in the critical early hours of infection, enabling timely and effective treatment.

How does the SEPSIS-xxpress system operate?

The system includes an instrument platform with an embedded touchscreen computer and test kits with single-use, disposable cartridges. Hospital staff can insert a patient's blood sample into a cartridge to start the test, with results presented on-screen in under three hours.

When was Molecular Detection founded?

Molecular Detection was founded in February 2007.

What is the current status of Molecular Detection?

Molecular Detection is currently inactive, as of October 2016.

In which sector does Molecular Detection primarily operate?

Molecular Detection's primary sector is Health Tech & Life Sciences, specifically focusing on Medical Devices and Diagnostics Devices.

What is Molecular Detection's employee count?

Molecular Detection has an employee count in the 11-50 range.

What is the product stage of Molecular Detection's offering?

Molecular Detection's product is in the R&D stage.

Sectors & technology

Tags